

Asymchem Expands Sterile Manufacturing Excellence with **New Cartridge Line**

Asymchem has reached a significant milestone in the expansion of its **parenteral production capacity**. The newly constructed sterile manufacturing facility at the TJ4 site is strategically designed to support the growing demand for **oligonucleotide and peptide drugs (TIDES)**.

By integrating high-containment, large-scale aseptic processing lines, Asymchem is uniquely positioned to provide global partners with seamless supply assurance from clinical development through commercial launch.

Pre-filled Syringe (PFS) Line



Compliance: Achieved full GMP status in December 2025.

Throughput: Features a batch capacity of **150,000 units** and a total annual capacity of up to **50 million units**.

Track Record: The line has already successfully delivered multiple clinical batches and completed process validation for a key project.

Current Status: Multiple clinical and commercial projects are currently underway.

Advanced Cartridge Line

Timeline: Scheduled to achieve full GMP compliance in Q2 2026.


Scale: Engineered for high-volume production with **330,000 units** per batch and an annual capacity reaching **100 million units**.

Market Demand: The line has already secured commercial orders and is currently the subject of active negotiations with several global partners.



Accelerating the Path from Early Development to Commercialisation through **API Development Workflows**

Asymchem Sandwich seamlessly integrates **High Throughput Experimentation (HTE)**, **engineering**, **process chemistry**, **analytical science** and **cGMP manufacturing** into comprehensive API Development Workflows—delivering speed, quality, and regulatory compliance from pre-clinical to commercial launch.



By delivering a robust, end-to-end solution that accelerates time-to-market, mitigates risks, and ensures quality, Asymchem provides a solid foundation to advance projects from pre-clinical to commercialization.

